Business
Oxford Biomedica joins COVID-19 vaccine Consortium
Oxford Biomedica joins COVID-19 vaccine Consortium.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n RNS Number : 1368J\n Oxford Biomedica PLC\n 08 April 2020\n \n \n \n \n \n \n \n \n \n \n Oxford Biomedica joins Consortium to rapidly develop a COVID-19 vaccine candidate\n \n \n \n \n \n · \n \n Consortium led by Jenner Institute, University of Oxford \n \n \n \n · \n \n Fast-tracked clinical trial of ChAdOx1 nCOV-19 vaccine candidate starts this month\n \n \n \n \n \n \n \n \n \n Oxford, UK - 8th April, 2020: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Group\"), a leading gene and cell therapy group, announced today it has joined a Consortium led by the Jenner Institute, Oxford University, to rapidly develop, scale-up and manufacture a potential vaccine candidate for COVID-19, called ChAdOx1 nCov-19. This vaccine candidate is one of the leading vaccine candidates currently in development globally, and is expected to be the UK's first COVID-19 vaccine in clinical trials later this month. The Consortium is led by the Jenner Institute, University of Oxford and also includes the Vaccines Manufacturing and Innovation Centre (VMIC), Pall Life Sciences, Cobra Biologics and Halix BV.\n \n The Jenner Institute and the Oxford Vaccine Group have recruited individuals aged 18-55 from the Thames Valley area in the UK to study the vaccine's safety and efficacy (see https://www.covid19vaccinetrial.co.uk/). Oxford Biomedica will provide access to its large scale GMP manufacturing facilities for viral vectors, including its new Oxbox facility, to the Consortium as required, which, along with other Consortium manufacturing partners in the UK and internationally, would allow for scaled manufacturing capacity should the safety and efficacy of the vaccine candidate be confirmed in clinical trials.\n \n The Oxford vaccine candidate relies on adenoviral vector technology, ChAdOx1, developed at the Jenner Institute, in Oxford. It is seen as one of the most promising vaccine technologies for COVID-19 as ChAdOx1 has been shown to generate a strong immune response from one dose and it has demonstrated a good safety profile in pre-clinical and clinical trials conducted to date. No financial terms were disclosed.\n \n \n John Dawson, Chief Executive Officer of Oxford Biomedica, said:\n \"\n As an established clinical and commercial manufacturer of viral vectors, we are very...